Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-30T00:33:13.729Z Has data issue: false hasContentIssue false
  • English
  • Français

Alteration of plasma phospholipids distinguish schizophrenic patients from controls: A targeted metabolomics study

Published online by Cambridge University Press:  19 July 2023

M. Naifar ,
A. Tebani ,
F. Ducatez ,
C. Pilon ,
T. Plichet ,
M. Maalej ,
W. Guidara ,
M. Maalej ,
F. AYADI  and
S. Bekri
M. Naifar*
Affiliation:
Biochemistry Laboratory “Molecular Basis of Human Diseases”, LR19ES13, Sfax Medicine College, University of Sfax, Sfax, Tunisia
A. Tebani
Affiliation:
Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Rouen University Hospital, Normandie University, Rouen, France
F. Ducatez
Affiliation:
Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Rouen University Hospital, Normandie University, Rouen, France
C. Pilon
Affiliation:
Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Rouen University Hospital, Normandie University, Rouen, France
T. Plichet
Affiliation:
Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Rouen University Hospital, Normandie University, Rouen, France
M. Maalej
Affiliation:
Psychiatry C- Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia
W. Guidara
Affiliation:
Biochemistry Laboratory “Molecular Basis of Human Diseases”, LR19ES13, Sfax Medicine College, University of Sfax, Sfax, Tunisia
M. Maalej
Affiliation:
Psychiatry C- Department, Hedi Chaker University Hospital, University of Sfax, Sfax, Tunisia
F. AYADI
Affiliation:
Biochemistry Laboratory “Molecular Basis of Human Diseases”, LR19ES13, Sfax Medicine College, University of Sfax, Sfax, Tunisia
S. Bekri
Affiliation:
Department of Metabolic Biochemistry, UNIROUEN, INSERM U1245, CHU Rouen, Rouen University Hospital, Normandie University, Rouen, France
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia (SCZ) is one of the most severe mental disorders. Several elements involved in pathogenesis have been characterized recently. However, tools for diagnosis and risk prediction are limited. Elucidation of the underlying genomic and molecular mechanisms of SCA remains a challenge.

Objectives

In this study, we aimed to identify plasma biomarkers for SCZ using targeted metabolomics.

Methods

All enrolled patients were drug-free for at least 3 months prior to admission. Plasma from 31 SCZ patients and 70 matched controls were analyzed using the LC/MS- Api 4000 QTrap Sciex. A total of 188 targeted metabolites, including 21 amino acids, 21 biogenic amines and 145 lipids or lipid-related metabolites were analyzed. All data modeling and analysis is done using MetaboAnalyst 5.0

Results

There was no significant difference in the studied groups regarding BMI. Plasma Triglycerides, LDL-C, total proteins levels were significantly decreased in SCZ compared to controls. Heatmap identified 2 clusters with 25 significantly differentially expressed metabolites (FDR <0.05) between the drug-naïve group and the matched controls. The OPLS-DA score plot showed that the groups are clearly separated according to plasma phospholipids concentrations. Among these differential metabolites, the expression level of very long chain Phosphatidylcholines (PC 36 – PC p42) and acylcarnitines were significantly decreased in SCZ compared to controls, whereas sphingomyelin (SM) and lysoPC were significantly lower in drug-naive patients.

Conclusions

In this study, we found that plasma phospholipids were significantly dysregulated in the SCZ patients and could be a promising pathway to explore SCZ.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S615
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.